Although IgA is primarily known for its critical role as secretory IgA in mucous membrane immune functions, monomeric IgA antibodies have been successfully adapted to target tumor associated antigens such as HER2, EGFR, CD20, and GD2 in various in vitro and in vivo studies [1,2,3,4]. This evidence concerns the gene ERBB2 and neoplasm.